173 related articles for article (PubMed ID: 18472987)
1. Review of tipranavir in the treatment of drug-resistant HIV.
Streeck H; Rockstroh JK
Ther Clin Risk Manag; 2007 Aug; 3(4):641-51. PubMed ID: 18472987
[TBL] [Abstract][Full Text] [Related]
2. Tipranavir: PNU 140690, tipranivir.
Drugs R D; 2006; 7(1):55-62. PubMed ID: 16620137
[TBL] [Abstract][Full Text] [Related]
3. Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance.
Luna B; Townsend MU
Clin Ther; 2007 Nov; 29(11):2309-18. PubMed ID: 18158073
[TBL] [Abstract][Full Text] [Related]
4. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
5. Tipranavir: a protease inhibitor for HIV salvage therapy.
Dong BJ; Cocohoba JM
Ann Pharmacother; 2006; 40(7-8):1311-21. PubMed ID: 16788094
[TBL] [Abstract][Full Text] [Related]
6. Unique thermodynamic response of tipranavir to human immunodeficiency virus type 1 protease drug resistance mutations.
Muzammil S; Armstrong AA; Kang LW; Jakalian A; Bonneau PR; Schmelmer V; Amzel LM; Freire E
J Virol; 2007 May; 81(10):5144-54. PubMed ID: 17360759
[TBL] [Abstract][Full Text] [Related]
7. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials.
Hicks CB; Cahn P; Cooper DA; Walmsley SL; Katlama C; Clotet B; Lazzarin A; Johnson MA; Neubacher D; Mayers D; Valdez H;
Lancet; 2006 Aug; 368(9534):466-75. PubMed ID: 16890833
[TBL] [Abstract][Full Text] [Related]
8. Tipranavir: a review of its use in the management of HIV infection.
Orman JS; Perry CM
Drugs; 2008; 68(10):1435-63. PubMed ID: 18578560
[TBL] [Abstract][Full Text] [Related]
9. Response of feline immunodeficiency virus (FIV) to tipranavir may provide new clues for development of broad-based inhibitors of retroviral proteases acting on drug-resistant HIV-1.
Norelli S; El Daker S; D'Ostilio D; Mele F; Mancini F; Taglia F; Ruggieri A; Ciccozzi M; Cauda R; Ciervo A; Barreca ML; Pistello M; Bendinelli M; Savarino A
Curr HIV Res; 2008 Jun; 6(4):306-17. PubMed ID: 18691029
[TBL] [Abstract][Full Text] [Related]
10. Drugs in traditional drug classes (nucleoside reverse transcriptase inhibitor/nonnucleoside reverse transcriptase inhibitor/protease inhibitors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine).
Arribas JR
Curr Opin HIV AIDS; 2009 Nov; 4(6):507-12. PubMed ID: 20048718
[TBL] [Abstract][Full Text] [Related]
11. Tipranavir.
Plosker GL; Figgitt DP
Drugs; 2003; 63(15):1611-8. PubMed ID: 12887268
[TBL] [Abstract][Full Text] [Related]
12. Susceptibility of HIV-1 to tipranavir and other antiretroviral agents in treatment-experienced patients: The UTILIZE Study.
Baxter JD; Bhatti L; Coakley E; Bartczak J; McDonough M; Vinisko R; Piliero PJ
Curr HIV Res; 2010 Jun; 8(4):347-54. PubMed ID: 20353387
[TBL] [Abstract][Full Text] [Related]
13. Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir.
Doyon L; Tremblay S; Bourgon L; Wardrop E; Cordingley MG
Antiviral Res; 2005 Oct; 68(1):27-35. PubMed ID: 16122817
[TBL] [Abstract][Full Text] [Related]
14. Tipranavir: a protease inhibitor from a new class with distinct antiviral activity.
Yeni P
J Acquir Immune Defic Syndr; 2003 Sep; 34 Suppl 1():S91-4. PubMed ID: 14562864
[TBL] [Abstract][Full Text] [Related]
15. Tipranavir: a new option for the treatment of drug-resistant HIV infection.
Temesgen Z; Feinberg J
Clin Infect Dis; 2007 Sep; 45(6):761-9. PubMed ID: 17712762
[TBL] [Abstract][Full Text] [Related]
16. Food and Drug Administration analysis of tipranavir clinical resistance in HIV-1-infected treatment-experienced patients.
Naeger LK; Struble KA
AIDS; 2007 Jan; 21(2):179-85. PubMed ID: 17197808
[TBL] [Abstract][Full Text] [Related]
17. Clinical validation and applicability of different tipranavir/ritonavir genotypic scores in HIV-1 protease inhibitor-experienced patients.
Saracino A; Monno L; Tartaglia A; Tinelli C; Seminari E; Maggiolo F; Bonora S; Rusconi S; Micheli V; Lo Caputo S; Lazzaroni L; Ferrara S; Ladisa N; Nasta P; Parruti G; Bellagamba R; Forbici F; Angarano G
Curr HIV Res; 2009 Jul; 7(4):425-33. PubMed ID: 19601778
[TBL] [Abstract][Full Text] [Related]
18. Update on HAART in HIV.
Yeni P
J Hepatol; 2006; 44(1 Suppl):S100-3. PubMed ID: 16359748
[TBL] [Abstract][Full Text] [Related]
19. Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial.
Cahn P; Villacian J; Lazzarin A; Katlama C; Grinsztejn B; Arasteh K; López P; Clumeck N; Gerstoft J; Stavrianeas N; Moreno S; Antunes F; Neubacher D; Mayers D
Clin Infect Dis; 2006 Nov; 43(10):1347-56. PubMed ID: 17051504
[TBL] [Abstract][Full Text] [Related]
20. Role of tipranavir in treatment of patients with multidrug-resistant HIV.
Courter JD; Teevan CJ; Li MH; Girotto JE; Salazar JC
Ther Clin Risk Manag; 2010 Oct; 6():431-41. PubMed ID: 20957134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
